Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Neulasta® Clear all

Conditions: Breast Cancer, Neutropenia
Interventions: F-627, Neulasta; Drug
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Neutropenia
Interventions: F-627, Neulasta® (pegfilgrastim); Drug
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Anderson, Indiana

Conditions: Breast Cancer
Interventions: filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, adjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 3
States / cities: Cleveland, Ohio • Mentor, Ohio • Orange, Ohio

Conditions: Leukemia, Lymphoma
Interventions: bevacizumab, pegfilgrastim, rituximab, cyclophosphamide, pentostatin; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine; Drug · Procedure · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Mature B-Cell Lymphoma
Interventions: COPAD, COP, COPD M3, CYM, COP, COPADM8, CYVE; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Prostate Cancer, Pain
Interventions: Azacitidine, Docetaxel, Prednisone, GADD45α methylation and expression analysis, Pegfilgrastim, Filgrastim; Drug · Genetic
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
Interventions: Romidepsin, Gemcitabine, Oxaliplatin, Dexamethasone, Pegfilgrastim; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer
Interventions: Intervention A: Irinotecan; Oxaliplatin; Neulasta, Intervention B: Etoposide; Carboplatin; Neulasta; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Alcoholic Hepatitis
Interventions: Standard of care + pegfiltrastim, Standard of care; Drug
Lead sponsor: Timothy Morgan, MD; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Loma Linda, California • Long Beach, California • Los Angeles, California + 2 more

Conditions: Breast Cancer
Interventions: bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 522
States / cities: Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more

Conditions: Bone Pain in Stage I - III Breast Cancer
Interventions: Naproxen, Loratadine, Pegfilgrastim, Chemotherapy; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 83
States / cities: Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more

Conditions: Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions: Cabozantinib, Topotecan, Cyclophosphamide, Myeloid growth factor; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 6 Years to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Neuroblastoma
Interventions: Lorlatinib, Cyclophosphamide, Topotecan, Filgrastim/pegfilgrastim; Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 4
States / cities: Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas

Conditions: Bioequivalence
Interventions: CHS-1701, Pegfilgrastim; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Locally Advanced Pancreatic Cancer, Pancreatic Cancer
Interventions: FOLFOXA; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
Interventions: Prexasertib, Cyclophosphamide, Gemcitabine, filgrastim, peg-filgrastim; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 24 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Small Cell Lung Cancer, Ovarian Cancer
Interventions: LCL161, Topotecan, Pegylated GCSF (PEG-GCSF); Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: filgrastim, pegfilgrastim, docetaxel, trabectedin; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 37
States / cities: Burbank, California • Los Angeles, California • New Britain, Connecticut + 28 more

Conditions: Healthy Volunteers
Interventions: PEG-rhG-CSF, Neulasta (PEG-rhG-CSF); Drug
Lead sponsor: Adello Biologics, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Neutropenia, Breast Cancer
Interventions: SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 76
States / cities: Glendale, Arizona • Tucson, Arizona • Yuma, Arizona + 71 more

Conditions: Childhood Solid Tumors
Interventions: Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Months to 25 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Immunity, Humoral
Interventions: CHS-1701, Pegfilgrastim (Neulasta); Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 4
States / cities: Overland Park, Kansas • Cincinnati, Ohio • San Antonio, Texas + 1 more

Search by objective public record fields.

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Mature B-Cell Lymphoma And Leukemia Study III

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)

Pegfilgrastim in Patients With Alcoholic Hepatitis

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NOLAN: Naproxen or Loratadine and Neulasta

Cabozantinib With Topotecan-Cyclophosphamide

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®